In vitro fluconazole susceptibility of 1565 clinical isolates of candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines

Testore, Gian Piero; Dori, Luca; Buonomini, Anna Rita; Schito, Gian Carlo; Soro, O.; Fortina, G; Andreoni, Stefano; Carlone, Nicola; Tullio, Vivian; Andreoni, Massimo

doi:10.1016/j.diagmicrobio.2004.07.010

Cited by 11 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings confirm the worldwide pattern (12,19). The frequency of C. krusei (2.6%) in our study was also similar to the 1.8 to 2% reported by other authors (1,5,6,12,19), while the percentage of C. kefyr in our study was higher (2.2%) than that reported in previous studies in Italy and worldwide (0.6%) (5,13,19). C. kefyr may be considered an emerging pathogen (15); however, few data are available about this pathogen.…”

supporting

confidence: 80%

“…In agreement with the international literature (1, 5, 13), we found that in Turin, Italy, C. albicans was the most common yeast species but the C. albicans frequency (55.6%) was slightly lower than that reported by other authors both in Italy (3,19) and worldwide (5,7,12,13). Four hundred twenty-seven strains (39.7%) were non-C. albicans spp.…”

supporting

confidence: 78%

“…Among these, C. glabrata (18.7%) was the first most common yeast pathogen, followed by C. tropicalis (5.5%) and C. parapsilosis (4.7%). Our findings confirm the worldwide pattern (12,19). The frequency of C. krusei (2.6%) in our study was also similar to the 1.8 to 2% reported by other authors (1,5,6,12,19), while the percentage of C. kefyr in our study was higher (2.2%) than that reported in previous studies in Italy and worldwide (0.6%) (5,13,19).…”

contrasting

confidence: 34%

“…C. kefyr may be considered an emerging pathogen (15); however, few data are available about this pathogen. The frequency of C. norvegensis and C. valida did not vary markedly over the 5-year study period (data not shown) (5,13,19). Unusual Candida species (C. holmii, C. humicola, C. intermedia, C. lambica, C. lusitaniae, C. membranifaciens, C. rugosa, and C. utilis) constituted only a small percentage (1.4%) ( Table 1).…”

mentioning

confidence: 99%

“…The BIOMIC system provides a cost-effective means to electronically read and interpret test plates and to collect and transfer data; moreover, the BIOMIC system provides improved intra-and interlaboratory reading consistency (5,7,13,19).…”

mentioning

confidence: 99%

See 4 more Smart Citations

In Vitro Activities of Fluconazole and Voriconazole against Clinical Isolates of Candida spp. Determined by Disk Diffusion Testing in Turin, Italy

Mandras

Tullio

Allizond

et al. 2009

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

The in vitro activities of fluconazole and voriconazole against 1,024 clinical isolates of Candida spp. were determined by the agar disk diffusion test using the Clinical and Laboratory Standards Institute (CLSI) M44-A guidelines. The results of this investigation demonstrated the broad-spectrum in vitro activity of voriconazole, relative to that of fluconazole, against yeasts tested, in particular fluconazole-resistant isolates, such as Candida krusei that showed high susceptibility to voriconazole. The situation in Turin, Italy, is quite similar to that of the rest of Italy, reflecting the worldwide trend.

show abstract

supporting

confidence: 80%

supporting

confidence: 78%

contrasting

confidence: 34%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

In Vitro Activities of Fluconazole and Voriconazole against Clinical Isolates of Candida spp. Determined by Disk Diffusion Testing in Turin, Italy

Mandras

Tullio

Allizond

et al. 2009

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

Commercial Methods for Identification and Susceptibility Testing of Fungi

Moser

Wicker

2016

Manual of Commercial Methods in Clinical Microbiology

View full text Add to dashboard Cite

Design, synthesis, and evaluations of antifungal activity of novel phenyl(2H-tetrazol-5-yl)methanamine derivatives

Salake¹,

Chothe²,

Nilewar

et al. 2013

J Chem Biol

View full text Add to dashboard Cite

Fungal infections pose a continuous and serious threat to human health and life. The intrinsic resistance has been observed in many genera of fungi. Many fungal infections are caused by opportunistic pathogens that may be endogenous (Candida infections) or acquired from the environment (Cryptococcus and Aspergillus infections). So, new therapeutic strategies are needed to combat various fungal infections. Fluconazole shows good antifungal activity with relatively low toxicity and is preferred as first line antifungal therapy, but it has suffered from severe drug resistance. So, there is a need to design novel analogues by modification of fluconazole-like structure. A novel series of phenyl(2H -tetrazol-5-yl)methanamine derivatives were synthesized by reaction of α-amino nitrile with sodium azide and ZnCl 2 in presence of isopropyl alcohol. They were evaluated for antifungal activity against Candida albicans and Aspergillus niger and subjected to docking study against 1EA1.

show abstract

In vitro fluconazole susceptibility of 1565 clinical isolates of candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines

Cited by 11 publications

References 37 publications

In Vitro Activities of Fluconazole and Voriconazole against Clinical Isolates of Candida spp. Determined by Disk Diffusion Testing in Turin, Italy

In Vitro Activities of Fluconazole and Voriconazole against Clinical Isolates of Candida spp. Determined by Disk Diffusion Testing in Turin, Italy

Commercial Methods for Identification and Susceptibility Testing of Fungi

Design, synthesis, and evaluations of antifungal activity of novel phenyl(2H-tetrazol-5-yl)methanamine derivatives

Contact Info

Product

Resources

About